In Re Lorazepam & Clorazepate Antitrust Litigation

631 F.3d 537
CourtCourt of Appeals for the D.C. Circuit
DecidedJanuary 18, 2011
Docket08-5044
StatusPublished
Cited by35 cases

This text of 631 F.3d 537 (In Re Lorazepam & Clorazepate Antitrust Litigation) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Lorazepam & Clorazepate Antitrust Litigation, 631 F.3d 537 (D.C. Cir. 2011).

Opinion

631 F.3d 537 (2011)

In re LORAZEPAM & CLORAZEPATE ANTITRUST LITIGATION.
Blue Cross & Blue Shield of Massachusetts, et al., Appellees
v.
Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc., Appellants.

Nos. 08-5044, 08-5045.

United States Court of Appeals, District of Columbia Circuit.

Argued October 8, 2010.
Decided January 18, 2011.

*538 Jonathan M. Jacobson argued the cause for appellants. With him on the briefs were Seth C. Silber, D. Bruce Hoffman, and Ryan A. Shores. Neil K. Gilman entered an appearance.

Martin R. Lueck argued the cause for appellees. With him on the brief were Sara A. Poulos, James R. Safley, Sarah E. Hudleston, Robert T. Rhoad, and Ryan C. Tisch. Jeffrey Downey and Bethany M. Wimsatt entered appearances.

*539 Before: SENTELLE, Chief Judge, WILLIAMS and RANDOLPH, Senior Circuit Judges.

Opinion for the Court filed by Senior Circuit Judge RANDOLPH.

RANDOLPH, Senior Circuit Judge:

This is an appeal from the judgment of the district court, entered after a jury trial, awarding plaintiffs $76,823,943. The plaintiffs invoked diversity jurisdiction and alleged violations of state antitrust laws. Our opinion deals only with defendants' motion on appeal to dismiss for lack of jurisdiction.

Plaintiffs are four health insurance companies. They sued Mylan, a manufacturer of generic drugs, and two other companies engaged in the business of selling chemicals for pharmaceuticals. In support of diversity jurisdiction, plaintiffs alleged that they were citizens of Minnesota, Massachusetts and Illinois, and that defendants were citizens of Delaware, Pennsylvania, New York, New Jersey and West Virginia. Their principal claim, sounding exclusively in state law, was that defendants entered into exclusive licensing agreements enabling Mylan to raise the prices the insurance companies paid for two prescription anti-anxiety medications.

The insurance companies sued, in their words, "on behalf of themselves and as claims administrators for their self-funded customers." In the insurance industry, "self-funded customers" are entities—typically large corporations—providing health benefits directly to their employees using their own funds. See generally Allison K. Hoffman, Oil and Water: Mixing Individual Mandates, Fragmented Markets, and Health Reform, 36 AM. J.L. & MED. 7, 17-18 (2010). These entities contract with insurance companies such as plaintiffs, who provide claims-processing and other services to them in plaintiffs' role as "third-party administrators." It is the self-funded customers who bear the financial risks associated with providing insurance coverage.

On the eve of trial, Mylan and its codefendants filed a motion challenging the insurance companies' authority to bring damages claims on behalf of their self-funded customers. The district court first granted the motion but later allowed the claims to proceed under Rule 17 of the Federal Rules of Civil Procedure. Rule 17(a)(1) requires every action to "be prosecuted in the name of the real party in interest." The court, however, "may not dismiss an action for failure to prosecute in the name of the real party in interest until, after an objection, a reasonable time has been allowed for the real party in interest to ratify, join, or be substituted into the action." Fed.R.Civ.P. 17(a)(3).

The district court found that the insurance companies were not the real parties in interest "with respect to the claims for damages suffered by their self-funded customers." But it allowed the insurance companies to seek ratification of the claims. To do so, the insurance companies sent letters to their self-funded customers, giving them about a week to respond. The letters stated that if the customer did not opt out, it will be deemed to have consented to the insurance companies' representing it and would be bound by the result of the litigation. (We express no opinion on the validity of this ratification procedure.)

The suit proceeded to trial. The jury found Mylan and its co-defendants liable and determined that their violations were willful. Judgment was entered, and this appeal followed.

After the parties had filed their briefs, and a few days before oral argument, defendants filed a motion to dismiss, arguing for the first time that the district court *540 lacked jurisdiction because at least one (Minnesota Mining and Manufacturing Corporation (3M))—and potentially more—of plaintiffs' self-funded customers were from the same state as at least one of the defendants. The existence of these customers, defendants argued, destroyed "complete diversity" and stripped the court of power to hear the case.

The first question this argument raises is whether plaintiffs' self-funded customers must be counted as parties for diversity of citizenship purposes. We think they must. The claims of the self-funded customers were asserted at the outset. Those customers, not the named plaintiffs, were the ones who felt the effect of defendants' alleged violations with regard to the claims asserted on their behalf. And they were the ones who had the right to sue under the substantive law. See, e.g., Mass. Gen. Laws ch. 93A § 9. The plaintiff insurance companies no longer contend that the contracts with their self-funded customers validly assigned the asserted claims to them. At most, plaintiffs' authority extended to acting as agent for the self-funded customers in recovering damages on their claims. See Advanced Magnetics, Inc. v. Bayfront Partners, Inc., 106 F.3d 11, 17-18 (2d Cir.1997). The self-funded customers are therefore the "real and substantial" parties with respect to the claims asserted on their behalf. See Associated Ins. Mgmt. Corp. v. Ark. Gen. Agency, 149 F.3d 794, 796 (8th Cir.1998); Airlines Reporting Corp. v. S & N Travel, Inc., 58 F.3d 857, 862 (2d Cir.1995). As such, they must be treated as parties for diversity purposes. Navarro Sav. Ass'n v. Lee, 446 U.S. 458, 460-61, 100 S.Ct. 1779, 64 L.Ed.2d 425 (1980); Associated Ins. Mgmt. Corp., 149 F.3d at 796.

The effect of the self-funded customers on the district court's diversity jurisdiction turns on principles established in three Supreme Court decisions dating from the early 1800's. The first, Capron v. Van Noorden, 6 U.S. (2 Cranch) 126, 2 L.Ed. 229 (1804), was a diversity action for trespass. The complaint alleged that the defendant was a citizen of North Carolina, but it did not allege that the plaintiff was a citizen of a different state. After verdict for the defendant, the plaintiff appealed on the ground that his complaint was jurisdictionally defective. The Supreme Court agreed and set aside the judgment.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tierney v. Tierney
District of Columbia, 2023
Pool v. Continental Casualty Company
District of Columbia, 2023
Searcy v. Smith
District of Columbia, 2023
Celli v. Weingarten
District of Columbia, 2022
Farar v. Weston
District of Columbia, 2019
Health Care Serv. Corp. v. Mylan Labs., Inc.
261 F. Supp. 3d 14 (District of Columbia, 2017)
Davis v. Paulson
District of Columbia, 2017
F5 Capital v. Pappas
856 F.3d 61 (Second Circuit, 2017)
Smith v. Hendricks
140 F. Supp. 3d 66 (District of Columbia, 2015)
John Doe I v. Exxon Mobil Corp
69 F. Supp. 3d 75 (District of Columbia, 2014)
Bell v. United States Department of Health & Human Services
67 F. Supp. 3d 320 (District of Columbia, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
631 F.3d 537, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-lorazepam-clorazepate-antitrust-litigation-cadc-2011.